Martin Hunt (Aged 61)
Martin Hunt has over 30 years’ experience in large multi-nationals, start-ups and public companies with a strong track record of management success and fund raising in the life science sector. His previous roles include CEO of biomaterials company Tissue Science Laboratories plc. Mr Hunt is Programme Director of the NIHR translational funding programme Invention for Innovation (i4i) and a member of the NIHR Strategy Board. Martin is Chair of the Remuneration Committee and a member of the Audit Committee.
Stuart Ashman (Aged 53)
Stuart has over 20 years’ experience in the medical device and life science sectors and most recently was CEO of Onbone Oy (“Onbone”), a Finnish private equity-backed medical device company. In this role, he successfully established a global sales force and distribution network and led the growth of a multi-million pound business.
Prior to Onbone, Mr Ashman was President/CEO of Andover Healthcare Inc., a US-based wound management manufacturer, and before then, was President/CEO of TI Group, a UK-based medical/engineering company. Stuart also served as Senior VP, Global Sales & Strategic Marketing, BSN Medical (Biersdorf, Smith and Nephew) and was Director of Sales & Marketing at Smith & Nephew Plc, in its Woundcare, Casting & Bandaging division.
Manprit Randhawa (Aged 39)
Chief Financial Officer
Manprit joined the board of SkinBioTherapeutics plc in June 2022, following several years working as a CFO in PE-backed Saas technology businesses which included experience across finance and other operational areas of the businesses. Prior to this Manprit was CFO of Finnish med-tech growth stage business Onbone Oy, helping to scale and lead significant international growth of the business. Manprit was Group Financial Controller of AIM-listed technology business Kromek Group plc, where he played a key role in its successful IPO in 2013. Manprit is a qualified chartered accountant (ICAEW) and began his career in audit in London with Deloitte before moving to UNW in Newcastle upon Tyne.
Dr Catherine Prescott (Aged 59)
Catherine has over two decades of experience in research, management and business in the biotechnology, pharmaceutical and venture capital sectors. Founder/Director of the consultancy Biolatris Ltd., Non-Executive Director of Videregen Ltd., Chair of the Trakcel Ltd Advisory Board, Translation Advisory Group member of the Babraham Institute, and Member of the Board of Trustees IMET2000. She is also a visiting professor at Kings College (London) teaching on the MSc programme ‘Cellular Therapies from bench to market’ and Senior Associate for the Masters in Bioscience Enterprise (Cambridge University). Cathy is Chair of the Audit Committee and a member of the Remuneration Committee.
Danielle Bekker (Aged 46)
Danielle Bekker is Senior Executive with international experience in FMCG Innovation and Supply Chain. She held Global Innovation Director roles in two FTSE 10 organisations. She brings strong direct to consumer, supply chain management and governance skills having worked with big corporates and having launched her own business in the drinks industry. She advises medium-sized businesses on their innovation and commercialisation strategy.